CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 110 enrolled
Drug / intervention
Fluviral®biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00718120
NCT00718120Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of a Single Injection of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral® (2008 - 2009 Season) in Adults Aged 18 to 60 Years and Over 60 Years.

GlaxoSmithKline·interventional·Posted Jul 18, 2008·Updated Jun 26, 2019

In Brief

A Phase 3 clinical trial evaluating Fluviral® for Influenza Vaccines. Completed, enrolled 110 participants across 1 site.

Detailed Summary

This study will evaluate the immunogenicity and safety of GSK Biologicals' Trivalent split virion influenza vaccine Fluviral for the 2008-2009 season in adults over the age of 18.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza Vaccines
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 18, 2008
Enrollment StartJul 18, 2008
Primary CompletionAug 9, 2008
TodayJul 2, 2026
Enrollment to primary: 21 daysPosted 18.0 years ago

Interventions

Fluviral®biological

One intramuscular injection into the deltoid region of the non-dominant arm